Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

TF Capital

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 45
Average round size
info
The average size of a deal this fund participated in
$39M
Portfolio companies 38
Rounds per year 4.09
Lead investments 2
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.16
Exits 4
Key employees 1
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Medical
  • Therapeutics
Summary

The venture was found in Asia in China. The main office of represented VC is situated in the Pudong.

The fund has exact preference in a number of founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight ZAI Lab, Antengene Corporation, Asieris Pharmaceuticals. Among the most successful fund investment fields, there are Biopharma, Pharmaceutical. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China.

The fund is constantly included in 2-6 investment rounds annually. The increased amount of exits for fund were in 2017. Deals in the range of 10 - 50 millions dollars are the general things for fund. This TF Capital works on 22 percentage points less the average amount of lead investments comparing to the other organizations. Considering the real fund results, this VC is 13 percentage points less often commits exit comparing to other organizations. The top activity for fund was in 2018. Despite it in 2019 the fund had an activity.

The typical case for the fund is to invest in rounds with 3-4 participants. Despite the TF Capital, startups are often financed by Qiming Venture Partners, Sequoia Capital China, Kleiner Perkins. The meaningful sponsors for the fund in investment in the same round are Qiming Venture Partners, Sinopharm Capital, Sequoia Capital China. In the next rounds fund is usually obtained by Sequoia Capital China, OrbiMed, Lapam Capital.

Besides them, we counted 1 critical employee of this fund in our database.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of TF Capital:
Typical Co-investors
TF Capital is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after TF Capital:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from China
Funds with similar focus located in China:
Funds with the same geo focus
Funds with similar geography of portfolio companies:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
APG Asset Management Heerlen, Limburg, The Netherlands
Blinc Advisors -
Bridford Investments -
DominateFund California, San Francisco, United States
Emerald Invest British Columbia, Canada, Vancouver
Lighthouse Capital Partners California, Menlo Park, United States
Polaris Industries Medina, Ohio, United States
Psilos Group New York, New York, United States
ZMT Capital California, Palo Alto, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Sanegene Bio

Biopharma
Health Care
Medical
$80M01 Dec 2023 Boston, Massachusetts, United States

XinjingZhiyuan

$30M15 Mar 2023 -

Allorion Therapeutics

Medical
Pharmaceutical
Therapeutics
$50M09 Mar 2023 Natick, Massachusetts, United States

AskGene Pharma

Biotechnology
Health Care
Pharmaceutical
$20M09 May 2022 Camarillo, California, United States

UniXell

Biotechnology
Medical
$30M14 Mar 2022 Shanghai, Shanghai, China

Chemsemi

Information Technology
$154M21 Jan 2022 Yangzhou, Jiangsu, China

Hesguard

Eyewear
Medical
Medical Device
$15M26 Dec 2021 Suzhou, Jiangsu, China

Allorion Therapeutics

Medical
Pharmaceutical
Therapeutics
$40M24 Nov 2021 Natick, Massachusetts, United States

Positive Sequence Biology

Biopharma
Biotechnology
Genetics
$46M08 Nov 2021 Shanghai, Shanghai, China
News
ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform

– ShouTi Inc. announced the close of a $100m Series B financing round.
– The round was led by BVF Partners. Additional new investors include Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Lilly Asia Ventures, Monashee Capital, Sage Partners, Stork Capital, Surveyor Capital (a Citadel company), TCG X, Terra Magnum Capital Partners, Woodline Partners, and co-founder and strategic partner Schrödinger.
– Existing investors also participated in the financing, including Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital and Wuxi AppTec.

Regor Therapeutics Announces Completion of $90 Million Series B Financing

– Regor Therapeutics announced the successful completion of $90m Series B financing.
– The round was led by Lilly Asia Ventures and included participation from Loyal Valley Capital, Lanting Capital, TF Capital and Vertex Ventures China.
– Regor Therapeutics was established with initial series A strategic investment from Qilu Pharmaceutical Group, a well-known Chinese pharmaceutical company.
– Regor Therapeutics is a clinical stage company dedicated to the discovery and development of innovative and clinically differentiated medicines by leveraging the proprietary CARD (Computer Accelerated Rational Discovery) Platform, seamlessly integrating structural biology, computational chemistry, therapeutic biology, medicinal chemistry, and clinical development.
– Regor has assembled a world-class scientific team and demonstrated high efficiency in producing best- and first-in-class molecules.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent TF Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 45
Average round size 39M
Rounds per year 4.09
Peak activity year 2021
Lead investments 2
Follow on index 0.16
Exits 4
Group Appearance index 0.91

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Sanegene Bio

Biopharma
Health Care
Medical
$80M01 Dec 2023 Boston, Massachusetts, United States

XinjingZhiyuan

$30M15 Mar 2023 -

Allorion Therapeutics

Medical
Pharmaceutical
Therapeutics
$50M09 Mar 2023 Natick, Massachusetts, United States

AskGene Pharma

Biotechnology
Health Care
Pharmaceutical
$20M09 May 2022 Camarillo, California, United States

UniXell

Biotechnology
Medical
$30M14 Mar 2022 Shanghai, Shanghai, China

Chemsemi

Information Technology
$154M21 Jan 2022 Yangzhou, Jiangsu, China

Hesguard

Eyewear
Medical
Medical Device
$15M26 Dec 2021 Suzhou, Jiangsu, China

Allorion Therapeutics

Medical
Pharmaceutical
Therapeutics
$40M24 Nov 2021 Natick, Massachusetts, United States

Positive Sequence Biology

Biopharma
Biotechnology
Genetics
$46M08 Nov 2021 Shanghai, Shanghai, China
Crunchbase icon

Content report

The following text will be sent to our editors: